Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$1.53 +12.5%	$1.34	$0.86 ▼ $3.36	$92.68M	0.14	232,796 shs	919,417 shs
ANRO Alto Neuroscience	$3.91 +8.8%	$2.80	$1.60 ▼ $15.04	$105.60M	1.84	102,544 shs	157,542 shs
ATRA Atara Biotherapeutics	$12.34 +7.4%	$10.10	$5.01 ▼ $18.70	$86.66M	0.26	50,828 shs	90,718 shs
PASG Passage Bio	$7.54 +1.9%	$6.92	$5.12 ▼ $26.60	$23.97M	1.81	58,174 shs	47,497 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	0.00%	+7.75%	-4.97%	+50.00%	-46.32%
ANRO Alto Neuroscience	0.00%	+24.03%	+28.10%	+27.93%	-64.64%
ATRA Atara Biotherapeutics	0.00%	+0.41%	+0.90%	+72.83%	+70.21%
PASG Passage Bio	0.00%	+8.49%	+31.59%	+1.89%	-49.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABOS Acumen Pharmaceuticals	3.0481 of 5 stars	3.5	5.0	0.0	1.4	1.7	0.6
ANRO Alto Neuroscience	1.7202 of 5 stars	3.3	1.0	0.0	1.1	0.8	1.3
ATRA Atara Biotherapeutics	4.6691 of 5 stars	3.4	4.0	4.7	3.0	3.3	0.6
PASG Passage Bio	3.792 of 5 stars	3.5	5.0	0.0	2.6	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	3.00	Buy	$6.33	313.94% Upside
ANRO Alto Neuroscience	2.57	Moderate Buy	$8.50	117.56% Upside
ATRA Atara Biotherapeutics	2.80	Moderate Buy	$21.00	70.18% Upside
PASG Passage Bio	3.00	Buy	$91.75	1,116.84% Upside

Current Analyst Ratings Breakdown

Latest PASG, ATRA, ABOS, and ANRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/14/2025	PASG Passage Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$260.00 ➝ $67.00
8/13/2025	PASG Passage Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00
6/26/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00
6/17/2025	ABOS Acumen Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$1.93 per share	N/A
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$4.56 per share	N/A
ATRA Atara Biotherapeutics	$188.67M	0.46	N/A	N/A	($4.99) per share	-2.47
PASG Passage Bio	N/A	N/A	N/A	N/A	$12.04 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$102.33M	-$2.28	N/A	N/A	N/A	N/A	-81.39%	-61.96%	11/11/2025 (Estimated)
ANRO Alto Neuroscience	-$61.43M	-$2.39	N/A	N/A	N/A	N/A	-44.34%	-36.73%	11/11/2025 (Estimated)
ATRA Atara Biotherapeutics	-$85.40M	-$0.43	N/A	N/A	N/A	3.07%	-8.34%	6.61%	11/11/2025 (Estimated)
PASG Passage Bio	-$64.77M	-$18.16	N/A	N/A	N/A	N/A	-103.87%	-59.95%	11/12/2025 (Estimated)

Latest PASG, ATRA, ABOS, and ANRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ANRO Alto Neuroscience	-$0.57	-$0.65	-$0.08	-$0.65	N/A	N/A
8/12/2025	Q2 2025	ABOS Acumen Pharmaceuticals	-$0.54	-$0.68	-$0.14	-$0.68	N/A	N/A
8/12/2025	Q2 2025	PASG Passage Bio	-$4.00	-$2.96	+$1.04	-$2.96	N/A	N/A
8/11/2025	Q2 2025	ATRA Atara Biotherapeutics	-$0.32	$0.19	+$0.51	$0.19	$4.23 million	$17.58 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.26	5.97	5.97
ANRO Alto Neuroscience	0.18	18.43	18.43
ATRA Atara Biotherapeutics	N/A	1.70	1.70
PASG Passage Bio	N/A	3.05	3.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
ANRO Alto Neuroscience	N/A
ATRA Atara Biotherapeutics	70.90%
PASG Passage Bio	53.48%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	9.30%
ANRO Alto Neuroscience	11.13%
ATRA Atara Biotherapeutics	4.00%
PASG Passage Bio	5.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	20	60.57 million	54.94 million	Optionable
ANRO Alto Neuroscience	N/A	27.08 million	24.06 million	N/A
ATRA Atara Biotherapeutics	330	7.02 million	6.74 million	Optionable
PASG Passage Bio	130	3.18 million	3.02 million	Optionable

PASG, ATRA, ABOS, and ANRO Headlines

Recent News About These Companies

Wedbush Comments on Passage Bio's Q3 Earnings (NASDAQ:PASG)

August 16, 2025 | americanbankingnews.com

Passage Bio (PASG) Receives a Buy from TD Cowen

August 15, 2025 | theglobeandmail.com

Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade

August 15, 2025 | zacks.com

Canaccord Genuity Group Lowers Passage Bio (NASDAQ:PASG) Price Target to $67.00

August 15, 2025 | americanbankingnews.com

Wedbush Issues Positive Forecast for Passage Bio (NASDAQ:PASG) Stock Price

August 15, 2025 | americanbankingnews.com

Passage Bio price target lowered to $67 from $260 at Canaccord

August 14, 2025 | msn.com

Passage Bio Reports Q2 2025 Progress and Financials

August 13, 2025 | msn.com

Passage Bio reports Q2 EPS ($2.96) vs ($5.09) last year

August 12, 2025 | msn.com

Passage Bio Reports Promising Q2 2025 Financial Results

August 12, 2025 | msn.com

Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights

August 12, 2025 | globenewswire.com

Passage Bio Regains Nasdaq Compliance with Stock Price

July 29, 2025 | tipranks.com

Insider Buying: Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Acquires 13,123 Shares of Stock

July 25, 2025 | insidertrades.com

Passage Bio Announces 1-for-20 Reverse Stock Split

July 10, 2025 | globenewswire.com

Passage Bio, Inc. (PASG) Income Statement - Yahoo Finance

July 1, 2025 | finance.yahoo.com

PASG Passage Bio, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 138,800 Shares

June 27, 2025 | insidertrades.com

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

June 23, 2025 | globenewswire.com

Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development

May 17, 2025 | msn.com

Passage Bio : résultat d'exploitation de -16,459 millions de dollars au premier trimestre

May 13, 2025 | zonebourse.comZ

PASSAGE BIO, INC. : Wedbush persiste à l'achat

May 13, 2025 | zonebourse.comZ

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG, ATRA, ABOS, and ANRO Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$1.53 +0.17 (+12.50%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.52 -0.01 (-0.33%)

As of 08/22/2025 07:55 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Alto Neuroscience NYSE:ANRO

$3.91 +0.32 (+8.83%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$3.90 -0.01 (-0.18%)

As of 08/22/2025 06:35 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Atara Biotherapeutics NASDAQ:ATRA

$12.34 +0.85 (+7.40%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$12.39 +0.05 (+0.41%)

As of 08/22/2025 06:19 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Passage Bio NASDAQ:PASG

$7.54 +0.14 (+1.89%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$7.54 0.00 (-0.07%)

As of 08/22/2025 07:48 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time